Search Results - "Bowers, Mindy A."

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma by Sborov, Douglas W., Benson, Don M., Williams, Nita, Huang, Ying, Bowers, Mindy A., Humphries, Kristina, Efebera, Yvonne, Devine, Steven, Hofmeister, Craig C.

“…Summary Single‐agent post‐autologous transplant maintenance therapy with lenalidomide is standard of care for patients with multiple myeloma. The tolerability…”
Get full text

A phase I trial of flavopiridol in relapsed multiple myeloma by Hofmeister, Craig C., Poi, Ming, Bowers, Mindy A., Zhao, Weiqiang, Phelps, Mitch A., Benson, Don M., Kraut, Eric H., Farag, Sherif, Efebera, Yvonne A., Sexton, Jennifer, Lin, Thomas S., Grever, Michael, Byrd, John C.

“…Purpose Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and…”
Get full text

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma by Hofmeister, Craig C., Williams, Nita, Geyer, Susan, Hade, Erinn M., Bowers, Mindy A., Earl, Christian T., Vaughn, John, Bingman, Anissa, Humphries, Kristina, Lozanski, Gerard, Baiocchi, Robert A., Jaglowski, Samantha M., Blum, Kristie, Porcu, Pierluigi, Flynn, Joseph, Penza, Sam, Benson, Don M., Andritsos, Leslie A., Devine, Steven M.

“…Abstract Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with…”
Get full text

Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma by Hofmeister, Craig C., Bowers, Mindy A, Efebera, Yvonne A, Humphries, Kristina, Benson, Don M., Greenfield, Carli N, Sell, Megan, Devine, Steven M.

“…Abstract 3114 Post autologous transplant maintenance therapy for patients with multiple myeloma (MM) is standard of care (McCarthy et al, NEJM, 2012)…”
Get full text

Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance by Hofmeister, Craig C., Bowers, Mindy A, Baiocchi, Robert A., Lozanski, Gerard, Humphries, Kristina, Blum, Kristie A., Porcu, Pierluigi, Penza, Sam, Greenfield, Carli N, Sell, Megan, Earl, Christian Tyler, Zitesman, Joseph, Quinion, Carl, Lustberg, Mark E, Andritsos, Leslie A, Devine, Steven M.

“…Abstract 2004▪▪This icon denotes a clinically relevant abstract Autologous hematopoietic stem cell transplantation (HSCT) cures fewer than half of patients…”
Get full text

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma by Hofmeister, Craig C., Liu, Zhongfa, Bowers, Mindy A, Porcu, Pierluigi, Flynn, Joseph M., Christian, Beth, Baiocchi, Robert A., Benson, Don M., Andritsos, Leslie A, Greenfield, Carli N, Sell, Megan, Geyer, Susan, Byrd, John C., Grever, Michael R.

“…Abstract 2955 Deacetylase (DAC) inhibitors show promise as anti-neoplastic agents, the approved drugs are weak inhibitors of class I and II DACs or potent…”
Get full text

Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors by Hofmeister, Craig C., Rieser, Gisele, Bowers, Mindy A, Merritt, Lisa C, Greenfield, Carli N, Efebera, Yvonne A, Benson, Don M, Devine, Steven M, Moor, Janet S de

“…Abstract 3807 Multiple myeloma (MM) is an incurable clonal plasma cell cancer characterized by a microenvironment of inflammatory cytokines, specifically IL-6,…”
Get full text

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma by Hofmeister, Craig C., Bowers, Mindy A, Bingman, Anissa, Lozanski, Gerard, Baiocchi, Robert A., Falk, William, Benson, Don M., Efebera, Yvonne A, Humphries, Kristina, Sell, Megan, Greenfield, Carli N, Lustberg, Mark E, Vaughn, John L., Earl, Christian Tyler, Geyer, Susan, Devine, Steven M.

“…Abstract 4460 Multiple myeloma patients after autologous hematopoietic stem cell transplant (HSCT) achieve a minimal residual disease state, providing an…”
Get full text

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia by Hofmeister, Craig C., Bowers, Mindy A, Lee, Seungsoo, Phelps, Mitch A., Benson, Don M, Kraut, Eric H., Hicks, William J, Deam, Deidre, Johnson, Amy J, Farag, Sherif, Jones, Jeffrey A., Byrd, John C.

“…Abstract 1933 A pharmacokinetically derived schedule of flavopiridol administered as a 30 min intravenous bolus followed by 4-hour continuous intravenous…”
Get full text

The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development by Wear, Sandra M., Richardson, Paul G., Revta, Carolyn, Vij, Ravi, Fiala, Mark, Lonial, Sagar, Mitchell, Alaina R., Siegel, David S., Aleman, Adolfo, Jakubowiak, Andrzej J, Durecki, Diane E, Reece, Donna E., Gul, Engin, Chari, Ajai, Jagannath, Sundar, La, Lisa, Hofmeister, Craig C., Bowers, Mindy A, Stewart, A. Keith, Hagerty, Rachel, Wolf, Jeffrey L., Pelle-Day, Geraldine, Krishnan, Amrita, Duarte, Lupe, Zimmerman, Todd M., Larsen, Daniel, Kumar, Shaji, Birgin, Ann, Raje, Noopur S., Roy, Vivek, Maharaj, Michele, Fay, Joseph W., Messing, Tracey, Ott, Robert F, Tasca, Leah, Anderson, Kenneth C., Giusti, Kathy

“…Abstract 1024 The MMRC is a non-profit, disease-focused consortium founded in 2004. Sixteen North American member institutions with expertise in multiple…”
Get full text